# A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.

> **NCT02034006** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 200 (actual)

## Conditions studied

- Choroidal Neovascularization Secondary to Pathologic Myopia

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02034006
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-10
- **Primary completion:** 2016-07-15
- **Final completion:** 2016-07-15
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2019-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034006, "A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02034006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*